Dominique is COO at Orthonika since co-founding the company in 2015. She has wide experience of product, business and company development, starting as a Research Scientist for Unilever in the team that launched Clear Blue diagnostics through its Unipath subsidiary. She was Business Development Manager for GSK’s Wellcome Diagnostics subsidiary, licensing-in new product lines and transitioning the business through acquisition by Murex and subsequent 10x sale to Abbott. In 1999 she joined Imperial Innovations to build a portfolio of spin-outs such as Acrobot (sold to Stryker) and Protexeon (sold to Air Products) and became Head of Life Sciences Technology Transfer in anticipation of the company’s IPO in 2006. In 2009 she left Imperial to become CEO at London Genetics, raising £2m to deliver pharmacogenetic services in clinical development, and has since worked in various biotech executive and non-executive roles, including 2 years on the board of the BioIndustry Association and 5 years as a Trustee of the Genetics Society. She holds a BSc in Life Sciences and an MBA with a focus on Technology Entrepreneurship from Imperial College London. She is an LESi Certified Licensing Professional.
Our new website is coming soon
Revolutionising the treatment landscape of meniscus deficiency and joint preservation
Orthonika is a spin-out company from Imperial College London developing the Total Meniscus Replacement, a unique entirely anatomical replacement for the meniscus of the knee, that aims to reduce persistent pain and restore mobility for one of the largest orthopaedic unmet clinical needs today.

About us






Board of Directors
Professor Andrew Amis, FREng
Technical Director and Co-Founder
Max Graziosi
Non-Executive Director
Scientific Advisory Board
Mr Andy Williams MBBS FRCS (Orth) FFSEM (UK)
Consultant Specialist Knee Surgeon (Fortius Clinic)
Mr Tim Spalding MBBS FRCS (Tr & Orth)
Consultant Specialist Knee Surgeon (Cleveland Clinic)
Professor Andrew Amis, FREng
Technical Director and Co-Founder